Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality
Karel Smetana, Daniel Rösel, Jan Brábek
Abstract
The FDA-approved drugs raloxifene and bazedoxifene could be among the best candidates to prevent mortality in severe COVID-19 patients. Raloxifene and bazedoxifene inhibit IL-6 signaling at therapeutic doses, suggesting they have the potential to prevent the cytokine storm, ARDS and mortality in severe COVID-19 patients, as is being shown with humanized antibodies blocking IL-6 signaling. In addition, raloxifene and bazedoxifene are selective estrogen receptor modulators with strong antiviral activity.
Topics & Concepts
RaloxifeneCytokine stormSelective estrogen receptor modulatorARDSMedicineCoronavirus disease 2019 (COVID-19)PharmacologyEstrogen receptorInternal medicineLungCancerBreast cancerDiseaseInfectious disease (medical specialty)COVID-19 Clinical Research StudiesCancer, Stress, Anesthesia, and Immune ResponseCytokine Signaling Pathways and Interactions